Akari Therapeutics
A Revolution in Treating Autoinflammatory & Orphan Diseases
Main Content
A REVOLUTION IN
TREATING AUTOINFLAMMATORY
& ORPHAN DISEASES
VIEW PRESENTATIONS
VIEW PRESS RELEASES
VIEW PRESENTATIONS
VIEW PRESS RELEASES
We develop life-transforming treatments for autoinflammatory diseases involving the complement (C5) and leukotriene (LTB4) pathways.
Please be advised that our lead product candidate, Coversin, was recently renamed nomacopan following its acceptance as an International Nonproprietary Name by the World Health Organization.
RECENT PRESS RELEASES
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA)
Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress
Footer
LONDON
75/76 Wimpole Street London W1G 9RT UK
T: +44 (0)20.8004.0261
E: info@Akaritx.com
NEW YORK
135 W 41st Street, 5th Floor
New York, NY 10036
T: 929.274.7510
F: 646.843.9352
E: info@Akaritx.com
EXPANDED ACCESS POLICY
In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of Nomacopan (Coversin) to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.